For pediatric cancers that are high in stemness genes and low in MHC-peptide expression, immunotherapy approaches that are independent of MHC class I expression, such as bi-specific T cell engager antibodies (BiTE) and T cells engineered to express chimeric antigen receptors (CAR T), could be more efficient, provided that sufficient tumor specific (neo-)antigens are identified as targets [10]. Here, HLA-C is linked to cancer.